A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2017
At a glance
- Drugs ASP 0819 (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 09 May 2017 Planned End Date changed from 19 Jun 2018 to 14 Jun 2018.
- 09 May 2017 Planned primary completion date changed from 4 Jun 2018 to 31 May 2018.
- 27 Mar 2017 Status changed from not yet recruiting to recruiting.